Brae­burn bags $110M in launch cash as PDU­FA date rolls up; En­do sub­poe­naed for doc­u­ments on opi­oid painkillers

→ Af­ter fail­ing to get a liftoff on Nas­daq last year, Brae­burn has raised $110 mil­lion in mez­za­nine fi­nanc­ing to back the prospec­tive launch of CAM2038, an in­jectable for­mu­la­tion of buprenor­phine for opi­oid ad­dic­tion. The com­pa­ny has post­ed pos­i­tive Phase III da­ta on the drug and is now look­ing to set up a com­mer­cial launch, with the PDU­FA date loom­ing in a few days af­ter a pos­i­tive ad­vi­so­ry com­mit­tee vote. Up un­til now Ap­ple Tree has been the sole backer at Brae­burn. But this time Welling­ton Cap­i­tal Man­age­ment led the round, joined by Avista Cap­i­tal Part­ners, RA Cap­i­tal Man­age­ment, New Leaf Ven­ture Part­ners, Deer­field Man­age­ment, and Rock Springs Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER